ECSP24000004A - Derivados de 3(1oxoisoindolin2il)piperidina2,6diona y sus usos médicos - Google Patents
Derivados de 3(1oxoisoindolin2il)piperidina2,6diona y sus usos médicosInfo
- Publication number
- ECSP24000004A ECSP24000004A ECSENADI20244A ECDI202400004A ECSP24000004A EC SP24000004 A ECSP24000004 A EC SP24000004A EC SENADI20244 A ECSENADI20244 A EC SENADI20244A EC DI202400004 A ECDI202400004 A EC DI202400004A EC SP24000004 A ECSP24000004 A EC SP24000004A
- Authority
- EC
- Ecuador
- Prior art keywords
- 6dione
- hemoglobinopathies
- derivatives
- beta
- medical uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a compuestos de fórmula (I), composiciones farmacéuticas que los comprenden, y su uso para reducir los niveles de expresión de los motivos de dedos de zinc ampliamente interespaciados (WIZ), o para inducir la expresión de la hemoglobina fetal (HbF), y en el tratamiento de trastornos sanguíneos hereditarios (por ejemplo, hemoglobinopatías, por ejemplo, betahemoglobinopatías), tales como la enfermedad de células falciformes y betatalasemia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196422P | 2021-06-03 | 2021-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24000004A true ECSP24000004A (es) | 2024-02-29 |
Family
ID=82115547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20244A ECSP24000004A (es) | 2021-06-03 | 2024-01-02 | Derivados de 3(1oxoisoindolin2il)piperidina2,6diona y sus usos médicos |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12103919B2 (es) |
| EP (1) | EP4347580A1 (es) |
| JP (1) | JP2024520654A (es) |
| KR (1) | KR20240013812A (es) |
| CN (1) | CN117062811A (es) |
| AR (1) | AR126052A1 (es) |
| AU (1) | AU2022284366A1 (es) |
| BR (1) | BR112023024905A2 (es) |
| CA (1) | CA3215410A1 (es) |
| CL (1) | CL2023003561A1 (es) |
| CO (1) | CO2024000013A2 (es) |
| CR (1) | CR20230614A (es) |
| DO (1) | DOP2023000261A (es) |
| EC (1) | ECSP24000004A (es) |
| IL (1) | IL308094A (es) |
| JO (1) | JOP20230308A1 (es) |
| MX (1) | MX2023014327A (es) |
| PE (1) | PE20240657A1 (es) |
| PY (1) | PY2243958A (es) |
| TW (1) | TW202306570A (es) |
| UY (1) | UY39796A (es) |
| WO (1) | WO2022254362A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4667056A1 (en) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| AR130961A1 (es) | 2022-11-04 | 2025-02-05 | Bristol Myers Squibb Co | Compuestos y su uso para el tratamiento de hemoglobinopatías |
| US20250333407A1 (en) * | 2024-04-29 | 2025-10-30 | Bristol-Myers Squibb Company | Compounds and Their Use for Treatment of Hemoglobinopathies |
| CN118598797A (zh) * | 2024-05-17 | 2024-09-06 | 诚达药业股份有限公司 | 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法 |
| CN121605108A (zh) * | 2024-06-25 | 2026-03-03 | 标新生物医药科技(上海)有限公司 | 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| PL2536706T3 (pl) | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| US20120302605A1 (en) | 2010-11-18 | 2012-11-29 | Deuteria Pharmaceuticals, Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9133161B2 (en) | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| CA3018434A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| IL318681A (en) | 2016-10-11 | 2025-03-01 | Arvinas Operations Inc | Compounds and methods for targeted reduction of androgen receptor |
| AU2017367872B2 (en) | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| CN118834201A (zh) | 2016-12-01 | 2024-10-25 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| KR20190101406A (ko) | 2016-12-23 | 2019-08-30 | 아비나스 오퍼레이션스, 인코포레이티드 | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| KR102839545B1 (ko) | 2016-12-23 | 2025-07-29 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| CA3049912A1 (en) | 2017-01-26 | 2018-08-02 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| US11999802B2 (en) | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019079701A1 (en) | 2017-10-20 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11028088B2 (en) | 2018-03-10 | 2021-06-08 | Yale University | Modulators of BTK proteolysis and methods of use |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| KR20250020690A (ko) | 2018-06-29 | 2025-02-11 | 다나-파버 캔서 인스티튜트 인크. | 세레블론(crbn)에 대한 리간드 |
| US12060366B2 (en) | 2018-06-29 | 2024-08-13 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| US12234220B2 (en) | 2018-06-29 | 2025-02-25 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| EP3813834B1 (en) | 2018-06-29 | 2025-03-26 | Dana-Farber Cancer Institute, Inc. | New crbn modulators |
| BR122022012697B1 (pt) * | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| US12227488B2 (en) * | 2018-12-03 | 2025-02-18 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of Helios and methods of use |
| JP2022548095A (ja) | 2019-09-16 | 2022-11-16 | ノバルティス アーゲー | 接着分解剤及びその使用方法 |
| CN119019369A (zh) * | 2019-10-17 | 2024-11-26 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| CA3164832A1 (en) * | 2019-12-18 | 2021-06-24 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
-
2022
- 2022-06-01 UY UY0001039796A patent/UY39796A/es unknown
- 2022-06-01 KR KR1020237045016A patent/KR20240013812A/ko active Pending
- 2022-06-01 US US17/829,933 patent/US12103919B2/en active Active
- 2022-06-01 CN CN202280022964.9A patent/CN117062811A/zh active Pending
- 2022-06-01 PY PY202202243958A patent/PY2243958A/es unknown
- 2022-06-01 EP EP22731823.5A patent/EP4347580A1/en active Pending
- 2022-06-01 AR ARP220101454A patent/AR126052A1/es not_active Application Discontinuation
- 2022-06-01 WO PCT/IB2022/055131 patent/WO2022254362A1/en not_active Ceased
- 2022-06-01 AU AU2022284366A patent/AU2022284366A1/en not_active Abandoned
- 2022-06-01 MX MX2023014327A patent/MX2023014327A/es unknown
- 2022-06-01 CA CA3215410A patent/CA3215410A1/en active Pending
- 2022-06-01 PE PE2023003180A patent/PE20240657A1/es unknown
- 2022-06-01 JP JP2023574412A patent/JP2024520654A/ja active Pending
- 2022-06-01 TW TW111120484A patent/TW202306570A/zh unknown
- 2022-06-01 BR BR112023024905A patent/BR112023024905A2/pt not_active Application Discontinuation
- 2022-06-01 IL IL308094A patent/IL308094A/en unknown
- 2022-06-01 CR CR20230614A patent/CR20230614A/es unknown
-
2023
- 2023-11-29 JO JOJO/P/2023/0308A patent/JOP20230308A1/ar unknown
- 2023-11-29 DO DO2023000261A patent/DOP2023000261A/es unknown
- 2023-11-29 CL CL2023003561A patent/CL2023003561A1/es unknown
-
2024
- 2024-01-02 CO CONC2024/0000013A patent/CO2024000013A2/es unknown
- 2024-01-02 EC ECSENADI20244A patent/ECSP24000004A/es unknown
- 2024-09-03 US US18/823,254 patent/US20250026736A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117062811A (zh) | 2023-11-14 |
| AR126052A1 (es) | 2023-09-06 |
| EP4347580A1 (en) | 2024-04-10 |
| CR20230614A (es) | 2024-02-01 |
| BR112023024905A2 (pt) | 2024-02-20 |
| MX2023014327A (es) | 2023-12-13 |
| KR20240013812A (ko) | 2024-01-30 |
| IL308094A (en) | 2023-12-01 |
| DOP2023000261A (es) | 2023-12-29 |
| CO2024000013A2 (es) | 2024-01-25 |
| WO2022254362A1 (en) | 2022-12-08 |
| AU2022284366A1 (en) | 2023-10-26 |
| CA3215410A1 (en) | 2022-12-08 |
| UY39796A (es) | 2023-07-31 |
| PE20240657A1 (es) | 2024-04-04 |
| JOP20230308A1 (ar) | 2023-11-29 |
| US20230019617A1 (en) | 2023-01-19 |
| US12103919B2 (en) | 2024-10-01 |
| CL2023003561A1 (es) | 2024-06-28 |
| JP2024520654A (ja) | 2024-05-24 |
| US20250026736A1 (en) | 2025-01-23 |
| PY2243958A (es) | 2023-01-20 |
| TW202306570A (zh) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP24000004A (es) | Derivados de 3(1oxoisoindolin2il)piperidina2,6diona y sus usos médicos | |
| CO2022008243A2 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos | |
| BRPI0925036B8 (pt) | uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele | |
| AR054249A1 (es) | Tratamiento de enfermedades del tejido conectivo de la piel | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| AR112353A1 (es) | Compuesto de insulina acilada | |
| UY28209A1 (es) | Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos. | |
| MX2023000398A (es) | Analogos de insulina novedosos y usos de estos. | |
| JP2013525342A5 (es) | ||
| ES2703530T3 (es) | Composición cicatrizante y utilización | |
| BR112014008430A2 (pt) | preparação de ovos com propriedades de regeneração, analgésica e/ou anti-inflamatória | |
| RU2015152964A (ru) | Косметические или дерматологические композиции, комбинирующие ретинальдегид и глицилглицин олеамид, и их косметические или дерматологические применения | |
| RU2016103388A (ru) | Косметическая композиция, содержащая трехкомпонентную липидную ассоциацию для контроля сухости кожи | |
| MX382521B (es) | Nuevos compuestos bioaromaticos de propinilo, composiciones farmaceuticas y cosmeticas que contienen los mismos y usos de los mismos. | |
| El Mazouz et al. | Burning skin on face following the use of cloves (Syzygium aromaticum) | |
| Shah et al. | Clinical healing efficacy of Thumari gel (Securinega leucopyrus [Willd.] Muell) in the management of Non-healing Ulcer-A pilot study | |
| BR112021020356A2 (pt) | Composição cosmética tópica e usos da mesma | |
| PA8641601A1 (es) | Derivados del acido acetico con sustituyentes ciclohexilmetoxi, procedimiento para su preparacion y su uso como medicamentos | |
| SV2006002191A (es) | Derivados del acido acetico con sustituyentes ciclohexilmetoxi, procedimiento para su preparacion y su uso como medicamentos | |
| ATE458477T1 (de) | Pharmazeutische zusammensetzung enthaltend in assoziation ubidecarenon, dexpanthenol und chlorhexidine oder eines seiner pharmazeutischen unbedenklichen salze zur anwendung auf der haut | |
| BRPI0405483A (pt) | processo de obtenção de extrato padronizado de própolis, extrato assim obtido, suas formulações, produtos e usos |